Lv21
148 积分 2025-04-24 加入
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
2小时前
待确认
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
12天前
已完结
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
12天前
已完结
The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?
12天前
已完结
从研究者发起的临床研究“资助合同”审查引发的思考和建议
23天前
已完结
Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study
1个月前
已完结
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
1个月前
已完结
Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies
1个月前
已完结
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
1个月前
已完结
A sensitive method for detecting proliferation of rare autoantigen-specific human T cells
1个月前
已完结
皖公网安备34019202002308
